单核细胞来源的IL-1和IL-6对CAR T细胞所致细胞因子释放综合征和神经毒性有不同作用
该研究建立了一个重现CAR T细胞治疗相关细胞因子释放综合征(CRS)和神经毒性关键特征的小鼠模型。在白血病负荷高的人源化小鼠中,CAR T细胞清除肿瘤引发高热和IL-6升高,单核细胞是CRS期间IL-1和IL-6的主要来源。阻断IL-6受体可预防CRS但不能防止迟发性致死性神经毒性,而IL-1受体拮抗剂anakinra可同时消除CRS和神经毒性并显著延长无白血病生存期。
要点
- 单核细胞是CAR T细胞相关CRS中IL-1和IL-6的主要来源
- 阻断IL-6受体可预防CRS但未能防止迟发性神经毒性
- IL-1受体拮抗剂可同时消除CRS和神经毒性
核心结论
- 单核细胞来源的IL-1和IL-6对CAR T细胞所致CRS和神经毒性有不同作用,anakinra可同时消除二者。
研究设计与样本
- 研究采用人源化小鼠模型,在高白血病负荷下进行CAR T细胞治疗以重现CRS和神经毒性。
主要发现
- CAR T细胞清除肿瘤触发高热和IL-6水平升高,单核细胞是CRS期间IL-1和IL-6的主要来源。
- 单核细胞清除或托珠单抗阻断IL-6受体可预防CRS,但托珠单抗未能保护小鼠免于迟发性致死性神经毒性。
- Anakinra消除CRS和神经毒性,并显著延长无白血病生存期。
临床怎么用
- IL-1受体拮抗剂anakinra可能为同时管理CAR T细胞相关CRS和神经毒性提供治疗策略。
局限性
- 研究基于小鼠模型,结果需在临床研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity. Understanding the nature of these pathologies and developing treatments for them are hampered by the lack of appropriate animal models. Herein, we describe a mouse model recapitulating key features of CRS and neurotoxicity. In humanized mice with high leukemia burden, CAR T cell-mediated clearance of cancer triggered high fever and elevated IL-6 levels, which are hallmarks of CRS. Human monocytes were the major source of IL-1 and IL-6 during CRS. Accordingly, the syndrome was prevented by monocyte depletion or by blocking IL-6 receptor with tocilizumab. Nonetheless, tocilizumab failed to protect mice from delayed lethal neurotoxicity, characterized by meningeal inflammation. Instead, the IL-1 receptor antagonist anakinra abolished both CRS and neurotoxicity, resulting in substantially extended leukemia-free survival. These findings offer a therapeutic strategy to tackle neurotoxicity and open new avenues to safer CAR T cell therapies.
引用
- Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018. PMID: 29808007. doi:10.1038/s41591-018-0036-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。